Tolerability and surrogate efficacy parameters of a polymerized depot mixture pollen extracts without dilutional effect

To evaluate tolerability of subcutaneous immunotherapy, in a polymerized mixture ( / ) depot presentation.  A total of 47 poly-allergic patients received: an abbreviated schedule with three injections at weekly intervals or a cluster schedule with two administrations in 1 day. Both treatments contin...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2019-08, Vol.11 (12), p.1031-1042
Main Authors: Quiralte, Joaquín, Lara, María Angeles, Sánchez, Gemma Vanesa, Monteserín, Javier, Fernández, Luís, Gómez-Fernández, María Cruz, Madariaga, Begoña, Arilla, Carmen, Asturias, Juan Andrés, Begoña, Leire, Martínez, Alberto
Format: Article
Language:English
Subjects:
allergen mixture
Allergens
Allergies
Asthma
Clinical medicine
Clinical trials
Immunoglobulin E
Immunoglobulins
Immunology
Immunotherapy
Patients
Phleum pratense
Pollen
poly-allergic patient
polymerized extracts
rhinoconjunctivitis
subcutaneous immunotherapy
Vaccines
without dilutional effect
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate tolerability of subcutaneous immunotherapy, in a polymerized mixture ( / ) depot presentation.  A total of 47 poly-allergic patients received: an abbreviated schedule with three injections at weekly intervals or a cluster schedule with two administrations in 1 day. Both treatments continued with 3 monthly maintenance administrations. Two systemic reactions, (4.3%). One grade 0 and one grade I. No local reactions. Immunoglobulin levels, increased significantly at final visit versus baseline in sIgG and sIgG4; in both schedules and allergens, no significant changes in specific immunoglobulin E levels were detected. Cutaneous reactivity at final visit decreased significantly. Both administration schedules with polymerized mixture of / , presented an excellent tolerability profile and induced preliminary efficacy changes.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2019-0051